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Abstract
Benzo[a]pyrene (BaP) is an environmental pollutant that, based on evidence largely from in vitro studies, exerts its genotoxic 
effects after metabolic activation by cytochrome P450s. In the present study, Hepatic Reductase Null (HRN) and Hepatic 
Cytochrome b5/P450 Reductase Null (HBRN) mice have been used to study the role of P450s in the metabolic activation 
of BaP in vivo. In HRN mice, cytochrome P450 oxidoreductase (POR), the electron donor to P450, is deleted specifically 
in hepatocytes. In HBRN mice the microsomal haemoprotein cytochrome b5, which can also act as an electron donor from 
cytochrome b5 reductase to P450s, is also deleted in the liver. Wild-type (WT), HRN and HBRN mice were treated by i.p. 
injection with 125 mg/kg body weight BaP for 24 h. Hepatic microsomal fractions were isolated from BaP-treated and 
untreated mice. In vitro incubations carried out with BaP-pretreated microsomal fractions, BaP and DNA resulted in sig-
nificantly higher BaP–DNA adduct formation with WT microsomal fractions compared to those from HRN or HBRN mice. 
Adduct formation (i.e. 10-(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-7,8,9,10-tetrahydro-BaP [dG-N2-BPDE]) correlated with 
observed CYP1A activity and metabolite formation (i.e. BaP-7,8-dihydrodiol) when NADPH or NADH was used as enzy-
matic cofactors. BaP–DNA adduct levels (i.e. dG-N2-BPDE) in vivo were significantly higher (~ sevenfold) in liver of HRN 
mice than WT mice while no significant difference in adduct formation was observed in liver between HBRN and WT mice. 
Our results demonstrate that POR and cytochrome b5 both modulate P450-mediated activation of BaP in vitro. However, 
hepatic P450 enzymes in vivo appear to be more important for BaP detoxification than its activation.
Introduction
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous in 
the environment as a result of their formation by the incom-
plete combustion of organic matter (Baird et al. 2005; IARC 
2010). Benzo[a]pyrene (BaP) is the most commonly studied 
and measured of the PAHs (Arlt et al. 2015b; Krais et al. 
2016; Labib et al. 2012, 2016; Siddens et al. 2012; Wohak 
et al. 2016; Long et al. 2017) and it is classified by the Inter-
national Agency for Research on Cancer (IARC) as a human 
carcinogen (Group 1). The unavoidable exposure of the 
human race to PAHs makes a substantial contribution to the 
overall burden of cancer in humans (Baird et al. 2005; IARC 
2010; Phillips and Venitt 2012). A major source of exposure 
to BaP is tobacco smoke (Alexandrov et al. 2016); however, 
for non-smokers the principal sources can be dietary (Phil-
lips 1999) and from exposure to air pollution (IARC 2016).
BaP is a procarcinogen that requires metabolic activa-
tion before reacting with DNA and exerting its genotoxic 
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effects (Luch and Baird 2005; Phillips 2005). It is activated 
via cytochrome P450 (P450)-dependent monooxygenases 
with CYP1A1 and CYP1B1 playing the major role. BaP 
is oxidised initially to BaP-7,8-epoxide, which is then con-
verted to BaP-7,8-dihydrodiol by epoxide hydrolase (Baird 
et al. 2005; Luch and Baird 2005) (Fig. 1). BaP-7,8-dihy-
drodiol then undergoes further bioactivation by CYP1A1 
and CYP1B1 to form the ultimately reactive species, BaP-
7,8-dihydrodiol-9,10-epoxide (BPDE) (Fig. 1). BPDE reacts 
with DNA to form principally the pre-mutagenic adduct 
10-(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-7,8,9,10-tet-
rahydro-BaP (dG-N2-BPDE) (Arlt et al. 2008; Kucab et al. 
2015; Long et al. 2016).
P450 enzymes play an important role in the bioactivation 
of many carcinogens (Nebert and Dalton 2006; Rendic and 
Guengerich 2012) and a number of transgenic mouse lines 
(e.g. CYP-knockout or CYP-humanised) have been devel-
oped to study the contribution of individual P450 enzymes 
to chemical-induced genotoxicity and carcinogenesis (Arlt 
et al. 2011a; Buters et al. 2002; Kimura et al. 1999, 2003; 
Stiborova et al. 2012; Uno et al. 2004). However, due to 
the large number of CYP isoforms and their overlapping 
substrate specificities, it has been difficult to determine the 
in vivo role of P450 enzymes as a whole. We have used the 
Hepatic P450 Reductase Null (HRN) mouse model as an 
approach to overcoming this limitation (for review see Arlt 
et al. 2015a). HRN mice have a deletion in their hepatocytes 
of P450 oxidoreductase (POR), the predominant electron 
donor to P450 enzymes, specifically (Henderson et al. 2003). 
Experiments with HRN mice have indicated that hepatic 
P450 enzymes play a more important role in the detoxifica-
tion of BaP in vivo despite their importance for BaP activa-
tion in vitro (Arlt et al. 2008), because HRN mice treated 
with BaP formed up to 13-fold higher levels of BaP–DNA 
adducts than wild-type (WT) mice. Further investigations 
involving cellular localisation of BaP–DNA adducts by 
immunohistochemistry showed that HRN mice have ample 
capacity for the formation of BaP–DNA adducts (i.e. dG-
N2-BPDE) in liver; no differences in BaP–DNA adduct for-
mation was observed between hepatocytes (i.e. POR-defi-
cient cells) and non-hepatocytes (i.e. POR-proficient cells) 
(Arlt et al. 2012). This paradoxical result is echoed by other 
Fig. 1  Pathways of BaP biotransformation and BaP–DNA adduct 
formation catalysed by CYP1A1 and mEH. The three-stage path-
way, involving mEH, forming the ultimately reactive species BPDE 
that binds to guanine to form the dG-N2-BPDE adduct (adduct 1) 
is shown on the right. The two-stage pathway that does not involve 
mEH forms the second adduct (i.e. adduct 2) seen in in vitro studies 
is shown on the left; the structure of the adduct has not yet been elic-
ited, the adduct is probably derived from the reaction of 9-hydroxy-
BaP-4,5-epoxide with guanine residues in DNA. The diagram in the 
centre shows the roles of POR, Cyb5R and Cyb5 as electron donors 
to P450 enzymes such as CYP1A1 that are central to the biotransfor-
mation of BaP
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studies with Cyp1a1(-/-) knockout mice (Uno et al. 2004), 
which also indicate the role of CYP1A1 in BaP detoxifica-
tion in vivo (Nebert et al. 2013).
Although the specific enzyme(s) involved in the genera-
tion of BaP–DNA-binding species in the liver of HRN mice 
is not known, it is clear that the process does not produce a 
different reactive species from that formed in WT mice (Arlt 
et al. 2008, 2012). One hypothesis is that another electron 
donor to P450 enzymes may contribute to BaP–DNA adduct 
formation in the livers of HRN mice. Although POR is 
viewed as the predominant electron donor to P450 enzymes 
(Guengerich 2008), cytochrome b5 (Cyb5) can also act as the 
electron donor both in vitro and in vivo (Finn et al. 2008; 
Yamazaki et al. 2002). Cyb5 can modulate P450 activity 
in three ways: (1) by direct transfer of both electrons via 
cytochrome b5 reductase (Cyb5R) in a pathway independ-
ent of POR (Yamazaki et al. 1996a, b); (2) by the transfer 
of the second and rate-limiting electron from either POR or 
Cyb5R (Hildebrandt and Estabrook 1971); or (3) by acting 
as an allosteric modifier of the enzyme in a non-catalytic 
role that can enhance reactions for many, but not all, P450 
enzymes (Yamazaki et al. 2002). Cyb5 is both substrate and 
enzyme specific, and has been shown to both stimulate and 
inhibit P450 reactions. Therefore, it is difficult to predict the 
contribution of Cyb5 to xenobiotic metabolism.
Previously we found higher protein expression of Cyb5 
in HRN mice than in WT mice after repeated BaP exposure 
(Arlt et al. 2012). Similar results were found for microso-
mal epoxide hydrolase (mEH), another important enzyme 
involved in the formation of the DNA-reactive intermediate 
BPDE (Arlt et al. 2012). To investigate the role of Cyb5 
in the metabolic activation of BaP in vitro, studies using 
reconstituted systems were carried out. The results showed 
that even under conditions where POR levels were low, 
CYP1A1, Cyb5, and mEH were able to activate BaP into 
reactive species that bind to DNA (Stiborova et al. 2014). 
Further, both NADPH (cofactor for the POR system) and 
NADH (cofactor for the Cyb5/Cyb5R system) stimulated 
CYP1A1-mediated BaP bioactivation in vitro, suggesting 
that the NADH/Cyb5R/Cyb5 system can act as sole electron 
donor to CYP1A1-catalysed BaP bioactivation (Stiborova 
et al. 2016a, b). All these findings indicate that even low 
POR expression in the livers of HRN mice (probably in non-
parenchymal cells), in combination with the induction of 
Cyp1a1, Cyb5 and mEH by BaP, might be sufficient for effi-
cient BaP bioactivation in vivo, replacing NADPH-depend-
ent POR in the CYP1A1-catalysed activation of BaP (Sti-
borova et al. 2014). Given the in vitro data and the increased 
protein expression of Cyb5 in HRN mice after repeated BaP 
exposure (Arlt et al. 2012), it is possible that Cyb5 compen-
sates for the absence of POR in the HRN mice and stimu-
lates P450-mediated BaP bioactivation. By crossing HRN 
mice with the hepatic cytochrome b5 null (HBN) mouse, 
the hepatic cytochrome b5/P450 reductase null (HBRN) 
mouse model was developed (Henderson et al. 2013); these 
mice lack both POR and Cyb5 in the liver and have reduced 
hepatic P450 activity relative to the HRN mouse (Henderson 
et al. 2013). In the present study we have used both the HRN 
and HBRN mouse models to investigate the contribution of 
Cyb5 to the metabolic activation of BaP in vivo.
Materials and methods
Chemicals
Benzo[a]pyrene (BaP; CAS no. 50-32-8; purity > 96%) was 
purchased from Sigma-Aldrich (St Louis, MO). All other 
chemicals were of analytical purity or better.
Animal treatment
All animal experiments were carried at the University of 
Dundee out under licence in accordance with the Animal 
(Scientifc Procedures) Act (1986), as amended by EU Direc-
tive 2010/63/EU, and with local ethical approval. HRN (Por
lox/lox/CreCYP1A1) mice and HBRN (Cytb5lox/lox/Porlox/lox±
CreALB) mice on a C57BL/6 background were derived as 
described previously (Henderson et al. 2003, 2013). Ani-
mals were maintained in open-top cages, with free access 
to food (RM1 diet, Special Diet Services, Essex, UK) and 
water, and a 12-h light/dark cycle. Mice homozygous for 
the floxed Por locus (Porlox/lox) were used as WT. Groups of 
female HRN, HBRN and WT mice (3 months old, 25–30 g) 
were treated intraperitoneally (i.p.) with 125 mg/kg body 
weight (bw) (n = 3) of BaP for 1 day following a treatment 
protocol used previously to study BaP metabolism in HRN 
mice (Arlt et al. 2008, 2012). BaP was dissolved in corn 
oil at a concentration of 12.5 mg/ml. Control mice (n = 3) 
received solvent (corn oil) only. Animals were killed 24 h 
after the single dose and their tissues (liver, lung, fores-
tomach, glandular stomach, kidney, spleen, small intestine, 
bladder and colon) were collected, snap-frozen and stored 
at − 80 °C until analysis.
BaP–DNA adduct detection by 32P‑postlabelling 
analysis
Genomic DNA from whole tissue was isolated by a stand-
ard phenol–chloroform extraction method and DNA adducts 
were measured for each DNA sample using the nuclease 
P1 enrichment version of the thin-layer chromatography 
(TLC)–32P-postlabelling method as described previously 
(Arlt et al. 2008, 2012). After chromatography, TLC plates 
were scanned using a Packard Instant Imager (Dowers 
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Grove, IL, USA). DNA adduct levels were calculated as 
described (Phillips and Arlt 2014). Results were expressed 
as DNA adducts/108 nucleotides.
Preparation of microsomes
Hepatic microsomes from untreated or BaP-treated mice 
were isolated as described previously (Arlt et al. 2008). 
Microsomes were isolated from 3 pooled livers of each 
mouse model. Protein concentration in the microsomal frac-
tion was measured using the bicinchoninic acid protein assay 
with bovine serum albumin as standard. Pooled microsomal 
fractions were used for further experiments.
Enzyme activity assays and immunoblotting
The hepatic microsomal fractions were characterised for 
Cyp1a1 enzyme activity using Sudan I oxidation (Stiborova 
et al. 2002) and for Cyp1a1 and Cyp1a2 enzyme activities, 
we used 7-ethoxyresorufin O-deethylation (EROD) (Sti-
borova et al. 2005). POR enzyme activity was determined 
using cytochrome c (Arlt et al. 2003). Western blotting 
analysis using 4–12% bis–tris gradient gels and sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) were carried out as described previously (Kucab 
et al. 2012). After migration, the proteins were transferred 
onto polyvinylidene difluoride (PVDF) membranes and 
the following primary antibodies were used: anti-Cyp1a1 
1:1000 (sc-20772 (H-70), Santa Cruz Biotech), anti-POR 
(ab39995, Abcam), anti-Cyb5 1:750 (ab69801, Abcam), and 
anti-Cyb5R 1:1000 (ABIN453978, antibodies-online.com). 
The antibody to detect glyceraldehyde phosphate dehydro-
genase (Gapdh) 1:25,000 (MAB374, Chemicon) was used 
as loading control. The secondary horseradish peroxidase-
linked antibodies were as follows: anti-goat 1:10,000 (sc-
2020, Santa Cruz) anti-rabbit 1:10,000 (#170–5046, Bio-
Rad). The antigen–antibody complex was visualised using 
 SuperSignal® West Pico Chemiluminescent Substrate Kit 
(Thermo Scientific).
Microsomal incubations for BaP–DNA adduct 
formation
Incubation mixtures consisted of 50 mM potassium phos-
phate buffer (pH 7.4). Reduced nicotinamide adenine dinu-
cleotide (NADPH) or reduced form of nicotinamide adenine 
dinucleotide (NADH) (1 mM in each case), pooled hepatic 
microsomal fraction (0.5 mg/ml protein) from HRN, HBRN 
and WT mice (either untreated or pretreated with BaP), 
0.1 mM BaP (dissolved in 7.5 µl DMSO) and calf thymus 
DNA (0.5 mg) in a final volume of 750 µl. Incubations were 
carried out at 37 °C for 90 min (Arlt et al. 2008). Control 
incubations were carried out (1) without microsomes; (2) 
without NADPH or NADH; (3) without DNA and (4) with-
out BaP. After incubation, DNA was isolated by a standard 
phenol–chloroform extraction method. BaP–DNA adduct 
formation was determined by 32P-postlabelling as described 
above.
Microsomal incubations for studying BaP 
metabolism
Incubation mixtures contained 100 mM potassium phos-
phate buffer (pH 7.4), NADPH or NADH (1 mM), pooled 
hepatic microsomal fraction (0.5 mg/ml protein) and 50 µM 
BaP (dissolved in 5 µl DMSO) in a final volume of 500 µl. 
Incubations were carried out at 37 °C for 20 min. Control 
incubations were carried out (1) without microsomes; (2) 
without NADPH or NADH; (3) without BaP. After incuba-
tion, 5 µl of 1 mM phenacetin (PA) in methanol was added as 
an internal standard. BaP metabolites were extracted twice 
with ethyl acetate (1 ml), solvent evaporated to dryness, 
residues dissolved in 25 µl methanol and BaP metabolites 
were separated by high-performance liquid chromatography 
(HPLC) (Stiborova et al. 2014).
Results
Protein expression of XMEs
Expression of electron donor proteins (i.e. POR, Cytb5, 
Cytb5R) associated with the mixed-function oxidase system 
(i.e. P450) was probed for in the hepatic microsomal frac-
tions from BaP-treated and untreated (control) WT, HRN 
and HBRN mice (Fig. 2). POR was expressed only in WT 
mice and Cytb5 was expressed only in WT and HRN mice, 
as expected (Henderson et al. 2013, 2006). Cytb5R was 
expressed uniformly in all mouse lines. Treatment with BaP 
did not alter the levels of POR, Cytb5 and Cytb5R expres-
sion relative to controls. Cyp1a1 protein was greatly induced 
in all mouse lines by BaP treatment. The extent of Cyp1a1 
protein induction by BaP was similar in all mouse lines. A 
previous study showed increased protein expression of Cyb5 
in HRN mice after repeated (i.e. 5 days) BaP treatment (Arlt 
et al. 2012). No induction of Cyb5 was observed in HRN 
mice after BaP treatment here which is probably due to the 
single 24-h administration selected for this study.
Enzyme activity of XMEs
POR activity was detected in the hepatic microsomal frac-
tions from WT mice but not in knockout animals (Fig. 3a), 
as expected (Henderson et al. 2013, 2006). POR activity in 
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BaP-treated WT mice was slightly lower than in untreated 
animals (compare Fig. 3a and Supplementary Fig. 1A).
We used EROD (Fig. 3b, Supplementary Fig. 1B) to 
measure Cyp1a1 and Cyp1a2 enzyme activity and Sudan I 
oxidation as a measure of Cyp1a1 enzyme activity (Fig. 3c, 
Supplementary Fig. 1C). Cyp1a activity was significantly 
higher in hepatic microsomes from mice treated with BaP 
than those from untreated mice, regardless of the enzyme 
cofactor (NADPH or NADH) used in the reaction mixture. 
When NADPH was used, hepatic microsomes from BaP-
treated WT mice exhibited the highest levels of Cyp1a activ-
ity (Fig. 3b, c). Cyp1a activity was significantly lower in the 
hepatic microsomes from BaP-treated HRN mice which cor-
related with the lack of POR activity in these mice. Cyp1a 
activity in hepatic microsomes from BaP-treated HBRN 
mice was significantly lower compared to BaP-treated WT 
and HRN mice and showed the lowest level of Cyp1a activ-
ity when NADPH was present. For untreated mice Cyp1a 
activity was also lower in HRN and HBRN mice than in 
WT mice, but the effect was less pronounced compared with 
mice treated with BaP (Supplementary Fig. 1B and C).
When NADH was used in the reaction mixture, hepatic 
microsomes from BaP-treated HRN mice showed signifi-
cantly higher Cyp1a activity than the hepatic microsomal 
fractions from BaP-treated WT and HBRN mice (Fig. 3b, c). 
Using EROD as a measure for Cyp1a activity, hepatic micro-
somes from BaP-treated HBRN mice exhibited the lowest 
level of Cyp1a activity in the presence of NADH (Fig. 3b). 
When Sudan I oxidation was used as a measure for Cyp1a1 
activity, Cyp1a1 activity was similar in BaP-treated WT and 
HBRN mice (Fig. 3c). In untreated mice Cyp1a activity was 
lower in the absence of the electron donors when NADPH 
was used in the reaction mixture, with activity highest in 
WT mice and lowest in HBRN mice. When NADH was used 
in the reaction mixtures Cyp1a activity was highest in the 
HRN mice. Cyp1a activity measured by EROD activity was 
lowest in WT mice, but Cyp1a1 activity measured by Sudan 
I oxidation was lowest in the HBRN mice (Supplementary 
Fig. 1B and C).
Analysis of BaP metabolites by HPLC
Hepatic microsomes isolated from WT, HRN and HBRN 
mice were incubated with BaP and analysed by HPLC to 
determine the BaP metabolite profile. The total forma-
tion of metabolites in vitro was the highest in the hepatic 
microsomal fraction from BaP-pretreated WT mice when 
NADPH was used as cofactor, around threefold higher than 
when NADH was used (Supplementary Fig. 2A). It is note-
worthy that residual BaP and/or BaP metabolites were not 
detected in hepatic microsomes isolated from BaP-treated 
mice (Supplementary Fig. 4C). Representative HPLC chro-
matograms showing the BaP metabolite profiles are shown 
in Supplementary Fig. 4. Hydroxylated BaP metabolites 
and BaP-dihydrodiols, as well as BaP-diones, were identi-
fied and the structures are shown in Supplementary Fig. 5. 
Fig. 2  Western blot analysis 
of Cyp1a1, POR, Cyb5 and 
Cyb5R in the pooled microso-
mal fractions of untreated (lanes 
1–3) and BaP-treated (lanes 
4–6) WT, HRN and HBRN 
mice. Gapdh protein expression 
was used as a loading control. 
Representative images of the 
Western blotting are shown, and 
at least duplicate analysis was 
performed in separate experi-
ments
Cyb5R
POR
Cyb5
Gapdh
Cyp1a1
WT HRN HBRN WT HRN HBRN
TreatedUntreated
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We also detected a metabolite Mx whose structure has yet 
to be elucidated. The two major metabolites formed in all 
incubations were BaP-7,8-dihydrodiol and 3-hydroxy-BaP 
(Fig. 4). No BaP metabolites were detected by HPLC in 
control incubations without microsomes, without NADPH/
NADH-generating system or without BaP (Supplementary 
Fig. 4C and D).
With NADPH as cofactor the overall formation of BaP 
metabolites was significantly lower in hepatic microsomal 
fractions from BaP-pretreated HRN mice with formation of 
BaP-3,6-dione, 9-hydroxy-BaP, 3-hydroxy-BaP and the uni-
dentified metabolite Mx being significantly lower than with 
BaP-pretreated WT mice (Fig. 4). The lowest extent of over-
all BaP metabolite formation was in the hepatic microsomal 
fractions from BaP-pretreated HBRN mice (Supplementary 
Fig. 2A). All metabolites except for BaP-9,10-dihydrodiol 
were detected at significantly lower amounts compared 
with BaP-pretreated WT hepatic microsomes. BaP-9,10-di-
hydrodiol, BaP-4,5-dihydrodiol, BaP-7,8-dihydrodiol and 
3-hydroxy-BaP were at lower levels than with BaP-pre-
treated HRN hepatic microsomes (Fig. 4).
When NADH was used as cofactor the overall formation 
of BaP metabolites in hepatic microsomal fractions from 
BaP-pretreated HRN mice was significantly higher than with 
fractions from BaP-pretreated WT mice with all metabolites 
being formed in higher quantities. There was no significant 
difference between overall metabolite formation in hepatic 
fractions from BaP-pretreated WT and HBRN mice (Sup-
plementary Fig. 2A) with only BaP-9,10-dihydrodiol being 
significantly lower (Fig. 4). All metabolites except for BaP-
1,6-dione and Mx were significantly lower compared with 
BaP-pretreated HRN hepatic microsomes (Fig. 4). The rate 
of BaP metabolism in the hepatic microsomal fractions cor-
related with the levels of Cyp1a enzymatic activity and the 
cofactor used (NADPH or NADH).
The overall formation of BaP metabolites in the hepatic 
microsomal fractions from untreated mice was highest in 
WT mice when NADPH was used in the reaction mixture, 
whereas when NADH was used the highest formation of 
metabolites was seen in HRN mice (compare Supplementary 
Fig. 2A and Fig. 3a). This pattern is similar to that observed 
in microsomes from BaP-pretreated mice, correlating with 
Cyp1a activity. However, the amount of metabolites detected 
was lower (Supplementary Fig. 6B).
BaP–DNA adduct formation in vitro
We investigated the ability of hepatic microsomes isolated 
from control and BaP-treated WT, HRN and HBRN mice to 
catalyse BaP–DNA adduct formation in vitro (Supplemen-
tary Fig. 2B and 3B). The BaP–DNA adduct pattern obtained 
by 32P-postlabelling analysis from in vitro microsomal incu-
bations consisted of up to two major spots (Supplementary 
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Fig. 3  Enzyme activity in the pooled hepatic fractions of BaP-treated 
WT, HRN and HBRN mice using either NADPH or NADH as the 
cofactor. a POR activity was measured as nmol of cytochrome c/mg/
min and was detected only in microsomal fractions from WT mice. 
b Cyp1a enzyme activity was determined using the EROD assay 
with activity being expressed as pmol of resorufin/mg protein/min. c 
Cyp1a1 enzyme activity was determined by the oxidation of Sudan 
I to hydroxylated metabolites with activity being measured as nmol 
of total C-hydroxylated metabolites/mg protein/min. Values are given 
as mean ± SD (n = 3). ND not detected.  Statistical analysis was per-
formed by one-way ANOVA with Tukey’s multiple comparison test 
(*, compared to WT; #, compared to HRN. *P ≤ 0.05 **P ≤ 0.01, 
***P ≤ 0.001, ****P ≤ 0.0001)
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Fig. 7). One spot (assigned adduct 1) was previously identi-
fied as 10-(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-7,8,9,10-
tetrahydrobenzo[a]pyrene (dG-N2-BPDE) (Arlt et al. 2008). 
The other spot (assigned adduct 2), which has not yet been 
fully structurally identified, is likely derived from the reac-
tion of 9-hydroxy-BaP-4,5-epoxide with guanine residues in 
DNA (see Fig. 1) (Schoket et al. 1989; Nesnow et al. 1993; 
Fang et al. 2001). These two adducts result from the bio-
transformation pathways illustrated in Fig. 1. Essentially 
no BaP–DNA adducts were formed in control incubations 
with microsomes of BaP-pretreated WT mice without BaP, 
but were detectable in control incubations with microsomes 
of BaP-pretreated HRN and HRBN mice (Supplementary 
Fig. 7). These findings indicate that some BaP that was not 
detectable by HPLC is retained in hepatic microsomes of 
BaP-pretreated HRN and HRBN mice, being activated to 
form BaP–DNA adducts underlining the high sensitivity of 
the 32P-postlabelling method.
During in vitro incubations with WT microsomal frac-
tions from BaP-pretreated mice and with NADPH as cofac-
tor, adduct 2 was the predominant DNA adduct formed 
with the formation of dG-N2-BPDE (adduct 1) being much 
lower (Supplementary Fig. 8A). This was not seen with the 
hepatic microsomal fractions from BaP-pretreated HRN and 
HBRN mice, where formation of the dG-N2-BPDE adduct 
was greater than adduct 2 when NADPH was used in the 
reaction mix, and adduct 2 was not detected with NADH 
as cofactor (Supplementary Fig. 8B). When NADPH was 
used the greatest BaP–DNA adduct formation was seen with 
microsomal fractions from BaP-pretreated WT mice. There 
was a significant reduction in total DNA adduct formation 
in the microsomal fractions from BaP-pretreated HRN mice 
with a further, significant, reduction in adduct formation in 
microsomal incubation from BaP-pretreated HBRN mice 
(Supplementary Fig. 2B). When NADH was used, the high-
est total adduct formation was from the microsomal frac-
tions from BaP-pretreated HRN mice with adduct formation 
from BaP-pretreated WT and HBRN microsomal fractions 
being significantly lower (Supplementary Fig. 2B). The 
total amount of BaP–DNA adduct formation in the hepatic 
microsomal fractions correlated with the amounts of BaP 
metabolites formed and the particular enzymatic cofactor 
used (see Supplementary Fig. 2A).
Levels of adduct 1 (dG-N2-BPDE) in vitro strongly cor-
related with the amounts of BaP-7,8-dihydrodiol formed in 
hepatic microsomal fractions from BaP-pretreated mice, 
both with NADPH and NADH as cofactor (Fig. 5a). When 
NADPH was used as cofactor, relative to WT, the formation 
of BaP-7,8-dihydrodiol was lower in HRN microsomal frac-
tions and lowest in HBRN microsomal fractions, correlating 
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Fig. 4  Detection of BaP metabolites on HPLC from in vitro incuba-
tions with BaP and hepatic microsomal fractions from BaP-pretreated 
WT, HRN and HBRN mice using either NADPH or NADH as cofac-
tor. Values are given as mean ± SD (n = 3). Statistical analysis was 
performed by one-way ANOVA with Tukey’s multiple comparison 
test (*, compared to WT; #, compared to HRN. *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001)
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Fig. 5  a Formation of BaP-
7,8-dihydrodiol and dG-
N2-BPDE (adduct 1) during 
in vitro incubations with 
hepatic microsomal fractions 
from BaP-pretreated WT, 
HRN and HBRN mice using 
either NADPH or NADH 
as cofactor. b Formation of 
9-hydroxy-BaP and adduct 2 
during in vitro incubations with 
hepatic microsomal fractions 
from BaP-pretreated WT, HRN 
and HBRN mice using either 
NADPH or NADH as cofactor. 
Values are given as mean ± SD 
(n = 3). ND not detected. Statis-
tical analysis was performed by 
one-way ANOVA with Tukey’s 
multiple comparison test (*, 
compared to WT; #, compared 
to HRN. *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001, ****P ≤ 0.0001)
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with dG-N2-BPDE (adduct 1) formation in these microso-
mal fractions. The highest amounts of BaP-7,8-dihydrodiol 
were observed in HRN microsomal fractions with NADH as 
cofactor, with similar amounts being formed in microsomal 
fractions from WT and HBRN mice (Fig. 5a).
Using NADPH as cofactor the amounts of 9-hydroxy-BaP 
correlated with the levels of adduct 2 in hepatic microsomal 
fractions from BaP-pretreated mice (Fig. 5b). The amounts 
of 9-hydroxy-BaP were also the highest in HRN microso-
mal fractions when NADH was used as cofactor (Fig. 5b). 
As adduct 2 was not detectable in microsomal fractions of 
either HRN or HBRN BaP-pretreated mice no correlation to 
the amounts of 9-hydroxy-BaP formed was found. Because 
DNA adduct formation was quite low in microsomal frac-
tions from untreated mice (Supplementary Fig. 8), no cor-
relation to metabolite formation was attempted.
BaP–DNA adduct formation in vivo
The BaP–DNA adduct pattern obtained from in vivo treat-
ments consisted of one major adduct spot, dG-N2-BPDE 
(Supplementary Fig. 9). No DNA adducts were detected in 
tissues of untreated mice (data not shown). Of the organs 
tested (liver, lung, kidney, small intestine, spleen, forestom-
ach, glandular stomach, colon and bladder) there was no 
significant difference exhibited between the mouse mod-
els with the exception of the small intestine and the liver 
(Fig. 6). In the small intestines there were significantly 
higher levels of BaP–DNA adducts in HBRN mice than in 
WT mice. BaP–DNA adduct formation in the livers of HRN 
mice was ~ sevenfold higher than in WT mice. BaP–DNA 
adduct formation in HBRN mice was significantly lower 
than that observed in HRN mice, although there is no sig-
nificant difference between WT and HBRN mice (Fig. 6). 
This supports previous results with BaP-treated HRN mice 
(Arlt et al. 2008, 2012).
BaP–DNA adduct formation in the livers of BaP-treated 
WT, HRN and HBRN mice in vivo (Fig. 6) strongly cor-
related with the formation of BaP-7,8-dihydrodiol and dG-
N2-BPDE in hepatic microsomal fractions of BaP-pretreated 
mice (compare Fig. 5a). Collectively, these results support 
the notion that the Cyb5/Cyb5R systems strongly contribute 
to BaP–DNA adduct formation in HRN mice.
Discussion
The in vitro experiments in this study using pooled hepatic 
microsomal fractions clearly demonstrated that Cyb5 con-
tributes to the bioactivation of BaP: formation of BaP–DNA 
adducts and BaP metabolites correlated with Cyp1a 
enzyme activity, and was lessened by the loss of electron 
donors when NADPH was used as cofactor to examine 
the POR-dependent pathway. When the NADH-dependent 
Cyb5R pathway was investigated, there was higher Cyp1a 
enzyme activity in the microsomal fractions of HRN mice 
than in those of WT mice. In the microsomal fractions from 
HBRN mice the activity was significantly lower relative to 
WT mice, indicating that increased NADH-dependent activ-
ity is caused by the increased expression of Cyb5. These 
results correlate with those from experiments with recon-
stituted enzyme systems (Stiborova et al. 2014, 2016a) rein-
forcing the hypothesis that Cyb5 is contributing to the bio-
activation of BaP in the livers of HRN mice in the absence 
of POR.
The present in vivo results, however, contrast with the 
observations from the in vitro experiments when NADPH 
was used as cofactor. Whereas the bioactivation of BaP 
in vitro was reduced with the loss of electron donors and 
P450 activity, the in vivo results were different. In HRN 
mice there was a sevenfold increase in hepatic DNA adduct 
formation compared with WT mice, reflecting findings seen 
in previous studies (Arlt et al. 2008, 2012). DNA adduct for-
mation in the livers of HBRN mice was significantly lower 
than in HRN mice, further indicating a role for Cyb5 in 
the formation of DNA adducts in HRN mice. When NADH 
was used as cofactor, bioactivation of BaP in vitro (i.e. 
BPDE–DNA adduct formation) correlated with P450 activ-
ity and the formation of BaP-7,8-dihydrodiol (precursor of 
BPDE) in hepatic microsomal fractions. BPDE–DNA adduct 
formation in vitro was the highest in hepatic microsomal 
fraction from BaP-pretreated HRN mice and correlated with 
the degree of hepatic BPDE–DNA adduct formation in vivo, 
i.e. highest levels of dG-N2-BPDE were seen in the livers of 
BaP-treated HRN mice. These results again support the con-
clusion that the Cyb5/Cyb5R systems strongly contributes 
to BPDE–DNA adduct formation in the livers of HRN mice. 
However, the level of DNA adducts in the livers of HBRN 
mice was not significantly different from that in the livers of 
WT mice, which was unexpected.
Both the HRN and HBRN mice display no overt changes 
in phenotype, although they have steatotic livers as a con-
sequence of non-functioning P450-housekeeping activ-
ity involved in cholesterol metabolism (Henderson et al. 
2003). There is the potential that the high dose of BaP com-
bined with the steatotic livers could mean that some BaP is 
retained in the livers and is released and metabolised over 
a longer period when normally detoxification mechanisms 
would have allowed any remaining BaP to be excreted. 
Treatment of mice with doses of 125 mg/kg bw BaP has 
been shown to be carcinogenic when administered daily 
for 5 days (Hakura et al. 1998) and is the reason why this 
dose was used in the present study. A tenfold lower dose of 
BaP was also found to increase BaP–DNA adduct forma-
tion in the livers of HRN mice relative to WT mice (Arlt 
et al. 2012). Other groups have developed similar models 
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with liver-specific deletion of POR (liver-Por-null mouse 
models) (Wu et al. 2003). It is noteworthy that treatment 
of liver-Por-null mice with 40 mg/kg bw did not result in a 
significant change in liver retention of BaP relative to WT 
mice (Wang et al. 2017). Furthermore, in HRN mice the 
clearance of BaP was not significantly different from that in 
WT mice (Arlt et al. 2008). BaP clearance in HBRN mice 
has not been investigated in the present study.
The increased hepatic BaP–DNA adduct formation in the 
HRN mice indicates that, in accordance with other stud-
ies (Shi et al. 2010; Uno et al. 2004, 2006, 2001), P450 
activity in hepatocytes in vivo is more important for BaP 
detoxification than bioactivation. Evidence for this hypoth-
esis came from a study of BaP bioactivation in Cyp1a1(-
/-) mice. Treatment of these mice i.p. with BaP (500 mg/
kg bw) resulted in a fourfold increase in hepatic DNA 
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Fig. 6  Quantitative TLC 32P-postlabelling analysis of dG-N2-BPDE 
adducts in individual organs of WT, HRN and HBRN mice treated 
i.p. with 125 mg/kg bw BaP for 24 h. Values are given as mean ± SD 
(n = 3). Statistical analysis was performed by one-way ANOVA with 
Tukey’s multiple comparison test (*, compared to WT; #, compared 
to HRN. *P ≤ 0.05, ***P ≤ 0.001, ****P ≤ 0.0001)
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adduct formation relative to WT mice (Uno et al. 2001). 
Some WT and Cyp1a1(-/-) in the study were pretreated 
with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) to assess 
whether any other dioxin-inducible enzymes were able to 
contribute to BaP activation. These TCDD-pretreated mice 
had decreased levels of BaP–DNA adducts and enhanced 
clearance of BaP from the blood, indicating that the accu-
mulation of BaP–DNA adducts in Cyp1a1(-/-) mice could 
be due to the lack of Cyp1a1-mediated detoxification (Uno 
et al. 2001). Further studies with Cyp1a1(-/-), Cyp1a2(-/-
) and Cyp1b1(-/-) single-knockout, Cyp1a1/1b1(-/-) and 
Cyp1a2/1b1(-/-) double-knockout mice suggested that 
Cyp1b1 was responsible for the activation of BaP whilst 
Cyp1a1 was responsible for detoxification (Nebert et al. 
2013). Although these studies provide a rationale for the 
increased BaP–DNA adduct levels in the livers of HRN 
relative to WT mice, they do not explain the formation of 
BaP–DNA adducts in the livers of HRBN mice. These find-
ings may suggest that a P450-independent mechanism con-
tributes to the activation of BaP in HBRN mice. It is note-
worthy that DNA adduct formation of the dietary carcinogen 
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) 
was similar in the livers of reductase conditional null (RCN) 
and WT mice (Arlt et al. 2011b) whereas RCN mice treated 
with BaP formed 5.6-fold higher liver DNA adduct levels 
than WT mice (Arlt et al. 2012). Like HRN mice, RCN mice 
have a liver-specific deletion of POR and thus show the same 
phenotype (Arlt et al. 2015a). Although PhIP bioactivation 
is considered to be catalysed by CYP1A2, the results in the 
RCN model suggested that PhIP may be activated mainly by 
a non-P450 pathway in the livers or extra-hepatic P450s of 
RCN mice (Arlt et al. 2011b).
The existence of a P450-independent BaP activation 
mechanism has also been suggested by other studies. DNA 
adduct formation in AhR(-/-) mice treated i.p. with BaP was 
similar to WT mice, suggesting an AhR-independent BaP 
activation mechanism (Kondraganti et al. 2003). When BaP 
was administered orally to AhR(-/-) mice, however, DNA 
adducts levels were significantly higher than in WT mice 
and a slower rate of clearance was observed (Sagredo et al. 
2006), correlating to findings seen in BaP-treated Cyp1a1(-
/-) mice (Uno et al. 2004). Other enzymes have been sug-
gested to be responsible for the bioactivation of BaP as stud-
ies have demonstrated a role of prostaglandin H synthase 
(PTGS/COX) in the oxidation of BaP-7,8-dihydrodiol to 
BPDE (Marnett 1990; Wiese et al. 2001).
Previous investigations showed that there was no dif-
ference in Ptgs1 and Ptgs2 expression between HRN and 
WT mice when exposed to BaP (Arlt et al. 2008). Hepatic 
Ptgs2 expression was also compared between Cyp1a1(-/-) 
and Cyp1a1(+/+) mice treated with BaP and no differ-
ences were found (Uno et al. 2004). Nevertheless, it may 
be possible that basal expression of Ptgs/Cox in the livers 
of HRN and HBRN contributes to the bioactivation of 
BaP-7,8-dihydrodiol to BPDE, with oxidation of BaP to 
BaP-7,8-dihydrodiol still needing to be catalysed by a non-
P450/non-Ptgs/Cox pathway. Aldo–keto reductases (AKR) 
have also been implicated in the formation of BaP–DNA 
adducts, competing with P450 enzymes to activate dihy-
drodiols. The products of AKR-catalysed reactions are 
o-quinones that produce BaP-7,8-dione–DNA adducts 
(Huang et al. 2013; Jiang et al. 2005, 2006) distinctly dif-
ferent from those detected in this study. The analysis of 
BaP-7,8-dione–DNA adducts was beyond the scope of the 
present study. As indicated above AKRs metabolise dihy-
drodiols, but not BaP itself, which further questions their 
involvement in the processes observed in the current study.
Wang and colleagues (Wang et al. 2017) have proposed 
that, besides Ptgs/Cox and Akr, 5-lipoxygenase contributes 
to the hepatic bioactivation of BaP in liver-Por-null mice. 
These conclusions were based on in vitro experiments meas-
uring BPDE–DNA adduct formation (i.e. detection of BaP-
tetrols by LC–MS/MS analysis after DNA hydrolysis) using 
S9 fractions isolated from WT and liver-Por-null mice and 
using inhibitors of these enzymes. Although useful, mim-
icking in vivo phenotypes with inhibition profiles in vitro is 
not straightforward. First, inhibitors are usually not wholly 
specific. Second, as seen again in this study using hepatic 
microsomes, extrapolating in vitro data to in vivo results is 
often not straightforward. However, it may be appropriate to 
test some inhibitors of other oxidoreductases (e.g. Ptgs/Cox 
or Akr) in BaP-treated HBRN mice in vivo and determine 
the subsequent BPDE–DNA adduct formation in the livers 
of these animals.
Conversely, our results in BaP-treated HBRN mice may 
suggest a role for systemic transport of reactive BaP inter-
mediates (e.g. BPDE) to the liver. Besides the liver, other 
organs (e.g. lung) have been shown to mediate CYP-cata-
lysed bioactivation of BaP (Arlt et al. 2015b). Other stud-
ies in mice have demonstrated that blood components (i.e. 
serum) can facilitate the systemic transport of BPDE (Gins-
berg and Atherholt 1989). Thus, the livers of BaP-treated 
HBRN mice, which are considered largely deficient in 
CYP-mediated BaP activation, may still receive substantial 
quantities of DNA-reactive BaP intermediates (i.e. BPDE) 
or the proximate carcinogen (i.e. BaP-7,8-dihydrodiol) that 
originate from their CYP-mediated formation in extra-
hepatic tissues. It is noteworthy that reactive BaP metabo-
lites have been shown to be transferred from an activator cell 
to another target cell (Sebti et al. 1982), again illustrating 
efficient transfer of BPDE despite its reactivity. Other stud-
ies have shown that hepatocytes and non-parenchymal liver 
cells have capacity to catalyse BaP-derived DNA adduct 
formation (Horton et al. 1985). Thus, it is possible that BaP 
bioactivation in CYP-expressing non-parenchymal liver cells 
may contribute to BaP–DNA adduct formation in the livers 
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of HBRN mice. To investigate this, it would require isola-
tion and culture of hepatocytes and non-parenchymal liver 
cells from HBRN mice and exposure of these cells to BaP 
for subsequent BaP–DNA adduct analysis.
In summary, this study has shown that both Por and Cyb5 
contribute to the bioactivation of BaP in vitro and that Cyb5 
also plays an important role in vivo for BaP activation in 
the HRN mice. The presence of BPDE–DNA adducts in 
the livers of HBRN mice, however, raises the fundamental 
question of how BaP is being metabolically activated in the 
livers of HBRN mice despite the absence of both electron 
donors. It is clear that HBRN mice possess ample capacity 
to form hepatic BaP–DNA adducts that arise from BPDE, 
the same process that occurs in WT mice. The results from 
this study continue to question the role of P450 enzymes 
in the bioactivation and detoxification of BaP, as well as to 
suggest the potential for a P450-independent BaP activation 
mechanism which will require further investigation. Alter-
natively our results may also suggest the systemic circula-
tion of DNA-reactive BaP intermediate (i.e. BPDE) which 
originates from P450-mediated activation in extra-hepatic 
tissues contributing to the detection of BaP–DNA adducts in 
the livers of HBRN mice. Likewise, non-parenchymal liver 
cells may play a role in catalysing P450-mediated bioactiva-
tion of BaP in HBRN mice.
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